FINNENCE ▪ THE WIRE FILE
THE WIRE · № 55460
News▼ Bearish
Oura Puts IPO on Hold as Market Conditions Shift
KINDNews
DIRECTION▼ Bearish
SOURCES3
ENTITIES2
STORY SIZE3 RECORDS
FIRST SEEN2026-09-29 15:43 UTC
LAST UPDATE2026-09-29 15:50 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
IPO hold confirms choppy conditions for new listings.
Listing window remains shut
CATALYST TO WATCH
Improved market conditions
MAIN RISK
Company-specific
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 3 TIMES · FIRST 2026-09-29 13:02 UTC · LAST 2026-09-29 15:50 UTC2026-09-29 13:02 UTCNewsOura stock listing in limbo as smart ring startup delays IPO just days after launching it - Fast Company
2026-09-29 15:43 UTCNewsOura Puts IPO on Hold as Market Conditions Shift - cheddar.comCURRENT RECORD
2026-09-29 15:50 UTCNewsOura delays IPO - MedTech Dive
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDConsumer
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Phase 3 trial: Study to Assess the Long-term Safety of KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT) — Endo USA Inc., a Keenova Therapeutics Company2026-09-29 12:00 UTC
New Phase 3 trial: Study to Assess the Long-term Safety of KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT) — Endo USA Inc., a Keenova Therapeutics Company2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Study of Velaglucerase Beta ERT in Children With Gaucher Disease — CANbridge Life Sciences Ltd.2026-09-29 12:00 UTC
New Phase 3 trial: Study of Velaglucerase Beta ERT in Children With Gaucher Disease — CANbridge Life Sciences Ltd.2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity — Pfizer2026-09-29 12:00 UTC
New Phase 3 trial: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity — Pfizer2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Hoffmann-La Roche2026-09-29 12:00 UTC
New Phase 3 trial: A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Hoffmann-La Roche2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Seagen Inc.2026-09-29 12:00 UTC
Phase 3 results posted: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Seagen Inc.2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia — Otsuka Pharmaceutical Development & Commercialization, Inc.2026-09-29 12:00 UTC
Phase 3 results posted: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia — Otsuka Pharmaceutical Development & Commercialization, Inc.2026-09-29 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.